Catalyst Pharmaceuticals, Inc.- Virtual Exhibit Hall - EMG/EEG, and Neurophysiology in Clinical Practice 2021 – LIVESTREAM | Mayo Clinic School of Continuous Professional Development

Catalyst Pharmaceuticals, Inc. - Exhibitor
Company Website Contact Information: Tara Moreton Regional Account Manager tmoreton@catalystpharma.com (407) 230-4437 Contact me to schedule a meeting.	Virtual Exhibit Hall Home FIRDAPSE is the first and only FDA-approved, evidence-based therapy indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. INDICATION AND IMPORTANT SAFETY INFORMATION INDICATIONS AND USAGE: FIRDAPSE is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. CONTRAINDICATION FIRDAPSE is contraindicated in patients with: • A history of seizures • Hypersensitivity to amifampridine phosphate or another aminopyridine WARNINGS AND PRECAUTIONS Seizures: FIRDAPSE can cause seizures. Consider discontinuation or dose-reduction of FIRDAPSE in patients who have a seizure while on treatment. FIRDAPSE is contraindicated in patients with a history of seizures. Hypersensitivity: If a hypersensitivity reaction such as anaphylaxis occurs, FIRDAPSE should be discontinued and appropriate therapy initiated. ADVERSE REACTIONS The most common (> 10%) adverse reactions are: paresthesia, upper respiratory tract infection, abdominal pain, nausea, diarrhea, headache, elevated liver enzymes, back pain, hypertension, and muscle spasms. Please see full Prescribing Information for additional Important Safety Information. To report SUSPECTED ADVERSE REACTIONS, contact Catalyst Pharmaceuticals at 1-844-347-3277 (1-844-FIRDAPSE) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. FIRDAPSE Brochure LEMS Disease Brochure LEMS v. MG Infographic

Catalyst Pharmaceuticals, Inc. - Exhibitor

Company Website

Contact Information:
Tara Moreton
Regional Account Manager
tmoreton@catalystpharma.com
(407) 230-4437

Contact me to schedule a meeting.

Virtual Exhibit Hall Home

FIRDAPSE is the first and only FDA-approved, evidence-based therapy indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE:
FIRDAPSE is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.

CONTRAINDICATION
FIRDAPSE is contraindicated in patients with:
• A history of seizures
• Hypersensitivity to amifampridine phosphate or another aminopyridine

WARNINGS AND PRECAUTIONS
Seizures: FIRDAPSE can cause seizures. Consider discontinuation or dose-reduction of FIRDAPSE in patients who have a seizure while on treatment. FIRDAPSE is contraindicated in patients with a history of seizures.

Hypersensitivity: If a hypersensitivity reaction such as anaphylaxis occurs, FIRDAPSE should be discontinued and appropriate therapy initiated.

ADVERSE REACTIONS
The most common (> 10%) adverse reactions are: paresthesia, upper respiratory tract infection, abdominal pain, nausea, diarrhea, headache, elevated liver enzymes, back pain, hypertension, and muscle spasms.

Please see full Prescribing Information for additional Important Safety Information.

To report SUSPECTED ADVERSE REACTIONS, contact Catalyst Pharmaceuticals at 1-844-347-3277 (1-844-FIRDAPSE) or FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.

FIRDAPSE Brochure
LEMS Disease Brochure
LEMS v. MG Infographic

Mayo Clinic School of Continuous Professional Development

You are here

Catalyst Pharmaceuticals, Inc.- Virtual Exhibit Hall - EMG/EEG, and Neurophysiology in Clinical Practice 2021 – LIVESTREAM